- Spectrum Pharmaceuticals ( NASDAQ: SPPI ) on Friday said that its medicine Rolvedon was now commercial available.
- Rolvedon (eflapegrastim-xnst) injection was approved in the U.S. in September to decrease the incidence of infection, manifested by febrile neutropenia, in adult patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs linked with febrile neutropenia.
- Neutropenia occurs when the body has fewer neutrophils, a type of white blood cell.
- SPPI +12.94% to $0.43 premarket Oct. 21
For further details see:
Spectrum stock jumps 13% on commercial launch of Rolvedon